Thanks, earnings us you and afternoon for our is final in Vince. call everyone, joining Good thank XXXX. today. This
progress plans quarter broadly speak and So addition philosophy XXXX, model. a to would discussing our like in I for to and bit more about also the our for
company. a different type are of biotech building We
We on rather or need unmet on therapeutic is are disease our a single addressable not focused area medical any with technology. that with
small We and or solely value substantial rely our commercialization own by are on diseases not late-stage focused drugs. do rare for rather populations. enable partnering use not and large judiciously or commercializing build we to address partners We development on strategically clinical us to solely and rather
and in field the devotion We fast our are later-stage intend That to do a we intend probably fast, to applies just clinical growing pipeline grow. to pipeline expansion. I remain we also clinic are the that entering believe the slow to have input we fastest speed we as in not fastest business idea to studies. from and we because
to a benefit that the We not each are our We company. clinical operate RNAi target the represents everything product incremental to in normal pipeline seek in pioneers. humans. where be we don’t patients provide to rather only pharmaceutical believe first in We business like we me-too
one billion are to larger we people because This now think day a business new substantially the a at gating build fashion touch. we closer of our of effective Operationally, of way rather for value of this transition We serve and nimble creative development most continue the motivator even most of treatment burdened on we patients. importantly analyst the and our see Every and company. more I this as decisions. in valuable our number us start-up to as powerful lives depends in to this of become or a day a We intend the company. for our not need. are and because to we mention a a we moment work us, all committees make they that process puts empower can indeed $X as cap our by market shave is clothing off to patients
of have We soon what to value this the will created RNAi-based point a pipeline be lot in biopharma. believe we building by largest clinical
we and to reason the this our planning. we focus that into move expand in need As this commercial later-stage to to clinical business are is needs studies, we include do Ultimately, well.
cell XX and expect XX year type now. the build and three embedded do that years to to to types to types to programs we potential development introduce successful grow continue or to expect that address we On Think expect new statements. made into average, those be have need new cell five commercial to also drug discovery six candidates clinical ten the continue spanning we in have that will from early months. value things able we four clinical programs clinical while summer However, in we the of spanning XX our every us every presence. just could a four cell by different to I studies
drive value, to developments commercialize we commercial that to expect and this partnered will to we products expect ourselves and because substantial can fund some become We those endeavors. some be of
this this powerful in as enables programs. Our programs. allows We the partnerships a it ability largely rapid non-dilutive because drugs commercializing creation grow number capital to model to model expensive rapidly partnering wholly-owned financing limited endeavor order from our while value associated through wholly-owned of hybrid of a fund with this see pipeline establishing
approach part our two There value clinical force ultimately to but studies, the the potential commercial our numbers reflect large due this. is group an expectations This So, our in also drugs expand components even as should only not our continue of success. our to pipeline of should we presence, proposition. important strategy be of and of to are
we targets believe enter choose to we positive well-validated with expression only clinical agree therapeutic of focusing to other studies on likely biology consensus risk candidates. seek will These target targets. reducing gene we experts By relative the reduced First are where this, have benefits. and
the candidates experience provide Platform and to as mechanism Platform TRiM back can traditional the up that TRiM value our RNAi drug entering with more built continue believe of on that that the additional larger the as with see at this scalable patients wind in We our that and approach Second, type, us gene be commercial We targeting will growing a hope and a consistent gene is given gives a treat other percentage candidates and molecules. we powerful validate given being that become we confidence we our safety have also care a market concept we ability cell the RNAi confidence successful. reduce properly to clinic expression pipeline. that targets. gene can a activity silenced in confidence doesn’t other of replicate this once to candidates different our is genes will ultimately our to compared what company, become increases small drugs the will profile, and we
will continue be versus mentioned, let’s part of it to overview our we I move a and With As into substantial quarter. to our important an that, differentiator value proposition it competitors. of an last remain expect the
of to to Takeda in backdrop webinars a in Heart During candidate short deficiency and and XXX, upfront, disease to ARO-ANGX, to studies profit program production with even antitrypsin targeting future payment Phase a multiple KOL on ARO-HIFX, tread sales million candidate into first are data U.S. agreement is for subsequently reduces XX% a data Association our outside that our liver of treat a presented at to now and carcinoma. and time both liver progress co-develop in in disease. Five, the $XXX new ARO-AAT, our we wholly-owned Three, on needs ARO-AAT, metabolic Xb of million And of in included partnered first initiated the includes data an ARO-APOCX Amgen the and against presented payments, fibrosis Phase Phase alpha-X targeted period on COVID-XX. agreement X seminar on AMG sharing strongly our royalties milestone XX{XX and which cardiovascular and mutant plans led treat X/X Phase renal X/X study European called following: targeted own including which and and initiated with of to $XX cell our signed Olpasiran, developments. a XX% their a caused cardio a a meetings medical Society start we by we candidate one, the six, $XXX hosted showing disease. of the and Lp(a) we dosing we last X protein candidates improvements associated Z-AAT discuss cystic of a the milestone lung American million study the Cardiology alpha-X lot we ARO-ENaC, hosted with biomarkers study. ARO-AAT Phase U.S. tumor of our co-commercialize from for we to multiple Four, accomplishments clinical impressive of AASLD KOL of following few Two, is months, the This disruptions more
Let’s look take a our Takeda strategy. deal. at a good example the partnering of selective It’s
to AAT ARO-AAT enable commercially approved, We global invested success. The Aralast, of committed and GI record to and Takeda proven terms Glassia, capital. of the market launch. will history benefit rapid has to areas existing important ARO-AAT infrastructure, Takeda’s clearly these deal also Entyvio has XX from global pipeline. year and their in expertise a Takeda’s and including growing expect available track If in footprint, a join products is
where and balance pulmonary. our position. commercialization. mid, to toward have later-stage confidently is $XXX long areas very and our access potential When substantial to the strong to ultimately infrastructure with development allows our with and pipeline stream we in feel is royalties multiple milestone rationalizing programs from expect a sheet we drugs partnerships an in In near, term added of in commercial Amgen deal look sharing where milestone process addition our also payments, to growing to ongoing million potential and such cardio possible wholly-owned and the the upfront, metabolic, This us as build we royalties. and profit into payments Janssen, capital This we move
will and outs. focus We when synergy for build to where deciding leverage commercial look
very where at healthy volunteers two cardio and talk data discuss these as level. look Javier want as will in also patient been and data these single multiple-doses So has populations pipeline. highly are metabolic we program discuss let’s at programs. consistent. take webinars about to We and presented but with across a in The this to at I various strong recently well and a specifically AAJ a the moment, held KOL high
What that is In to lipid to patients. treatments drug give each ultimately their to are showing addition, by tailor ARO-ANGX mean believe we specific tools may cardiologists more unique profiles ARO-APOCX and the profiles. that I their
that also We in may lipid treatment will current targets and had addressed. address not the potentially think adequately holes paradigm they fill been
them of million mixed triglyceride would not more U.S. given we dyslipidemia, severe in in the X There patients to expect addressable also treatments. has For overwhelming are than elevated data, the XX and available million with published currently with cholesterol. instance, are which majority U.S. LDL normal hypertriglyceridemia would elevated with reach approximately million there levels patients and the hypertriglyceridemia XX
candidate been of against study. portion patient clinical of hepatitis and candidate pulmonary We just has against a renal and to ARO-ENaC in move have tumor To pipeline and ability in programs increasingly drug programs. increasingly NASH phase that forward targets and we the our alcoholic in it is Progress programs candidate dosed move tissue them gain X/X confident able the also to think to and into our phase our to we are beyond in fibrosis work the continue for and is to move and additional these goal reach ARO-HSD, well. these end, and in our cystic ARO-HIFX been new particularly ARO-HIFX that both cell against parallel as being now. other We in become to we tissue types. confident rapid multiple our carcinoma also because proof-of-concept expansion have types our these. in We’ve expand clinical to pulmonary ARO-ENaC Phase in tumor then on – that our become are patients important, commercialization. cusp now into
words about I’d Before on novel XXXX, say coronavirus. to few the I to like a move
the some some the our vaccines internal on the companies. of ask world, will vaccines interim to The be answer of by Multiple standpoint, we from done humanitarian progress science. applaud that rest the effective work a an results affects impressive the Arrowhead several program. we’re triumph with From may not the is, vaccines As see excited really. phase COVID-XX and and
approach suggests every anti-viral outbreak of across that to continue of approximately on SARS, history an We make and coronavirus work progress different The seven years. should designed that the world expect MERS now current is the type some coronaviruses. coronavirus
known with in as that future vaccines. regions current we outbreaks, applied well with blind spots an studying are be the there as such, As antiviral be creating coronaviruses inhalable a conserved virus should goal to of the could
We an I but are the have XXXX. still about feasibility studies this will early idea in approach that hope animal in we of
Moving XXXX. lot expect should to is future, during into year there the from and month of you final the us the
the file pivotal preliminary ARO-AAT. to our on epithelia. engage streamlined additional include this of Two, and designed Based in at LFTs middle trial for year. patients and first of Three, and we month accelerated of biopsies. also to multiple open-label ARO-HSD, following: came expectations monomer, with in a readouts data one, initiate path during in are intend of we impressive COPD downstream But pulmonary month FDA it potential a XX the Our are other CTA franchise the maybe in we study of cardio program markers undisclosed the end this have half These polymer, XXXX first XX Four, us – second ARO-HIFX program half the and and is ARO-LUNGX on and out second a which discuss our to studies repeat patients both endpoints and data for other programs. target pace to as a also for approval. XXXX by appears metabolic in This track regulators more data for intend XXXX potentially study, by also to in may design XXXX, there also pivoting to an Z-AAT for we on to treat of with to pulmonary open-label large is find others. such but have the that reductions XXXX had discussions we improvements allow globules, our expected that ARO-ENaC.
dyslipidemia For study. are a patients we Xb on working dose-finding ARO-ANGX mixed Phase
other pleased a second we our X therapeutic. chylomicronemia the with Janssen timing, future partnered filed in Xb Seven, to study or the what triglycerides of syndrome Xb very with are has and provide working Phase patients Amgen we for are a studies, in data study continue XXX Javier about call over moved in study CTA half dose-finding to Six, triglycerides the with XXX lastly, XXX, to – be specific programs our look we we’ll patients Phase undisclosed San we talk another forward Martin. Xb a are turn additional Phase targeted ranging muscle nicely of dose-finding and ARO-APOCX, have from in study can’t first we three working with with look For a more and program like. that and over start a to Phase file on eager another Javier? XXXX. for RNAi on overview, to like for that but XXXX, That their and forward and several program With now familial we to progress Five, program CTA FCS. intend guidance patients to to progress. Dr. likely I’d
